Browse All Grants
20,252 grants found
Showing 1,041 – 1,060 of 20,252 grants
Cancer Aging and Metabolism research experience Program (CAMP)
SUMMARY The Beckman Research Institute of City of Hope (COH) is a world-class cancer research institution and cancer hospital with a mission of turning science into practical benef...
Enhancing Primary Care Capacity for Cancer Survivorship Care Delivery in Community Health Clinics
PROJECT SUMMARY The US has over 18 million cancer survivors (persons diagnosed with cancer no matter where they are in the course of their disease), estimated to increase to 22 mil...
2024 Mutagenesis Gordon Research Conference and Seminar
Project Summary The 2024 Gordon Research Conference on Mutagenesis will explore cutting edge research into the mechanisms and consequences of changes in the genomic sequence of org...
Therapeutic Inhibition of MYC:TRRAP Interaction in Cancer
PROJECT SUMMARY The long-term product goal of this project is a small molecule cancer therapeutic targeting the MYC oncoprotein, which is a transcriptional factor that regulates ke...
The role of H3F3A and ATRX co-mutation in epigenetic dysregulation of developmental genes in pediatric high-grade glioma
PROJECT SUMMARY Pediatric high-grade gliomas (pHGG), which include diffuse midline glioma (DMG), are among the most lethal of all pediatric cancers, with survival rarely exceeding...
Targeting alternative isoform variation for TCR discovery in platinum-resistant ovarian cancer
PROJECT SUMMARY We present an interdisciplinary target discovery and T-cell receptor (TCR) therapy development program focused on platinum-resistant high-grade serous ovarian carci...
Therapeutic Inhibition of MYC:TRRAP Interaction in Cancer (I-Crops Supplement)
RESEARCH STRATEGY Executive Summary of Predicate SBIR or STTR Phase I Grant and Team cosMYC, Inc. intends to develop and commercialize small molecule cancer therapeutics that selec...
Taming two bacterial toxins into an anticancer agent with "sweets
In the United States, lung cancer is the most common cause of cancer-related deaths, with only 20.5% of the 5-year overall survival rate. Low lung cancer survival rates reflect the...
TO TITLE: A NOVEL MRNA VACCINE TO PREVENT TRIPLE NEGATIVE BREAST CANCERIDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS
Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer characterized by the absence of estrogen receptors (ER), progesterone receptors (PR), and HER2...
Impact of DNA Repair Pathway Interactions on the Molecular and Physiological Consequences of Methylation Damage
Project Summary/Abstract Here, we propose to study cancer etiology in the context of DNA damage caused by a methylating agent, N- nitrosodimethylamine (NDMA), a probable human carc...
Immune determinants modulating cancer development in Lynch Syndrome
SUMMARY: Lynch Syndrome (LS) represents a hereditary predisposition syndrome associated with DNA mismatch repair (MMR) pathway impairment. LS-associated tumors demonstrate a high l...
Deconstructing pineoblastoma origins to advance disease biology, modeling, and therapy
Pineoblastoma (PB) is an understudied, clinically aggressive embryonal tumor of the pineal gland diagnosed early in life. Due to its rarity, knowledge pertaining to the molecular a...
Unraveling Vascular Mediated Immune Exclusion in Melanoma
TITLE: Unraveling Vascular Mediated Immune Exclusion in Melanoma PROJECT SUMMARY Melanoma remains the primary cause of skin cancer-related deaths. A significant number of patients...
A network approach to interrogate cellular plasticity and drug resistance in cancer
ABSTRACT We will address a critical problem in clinical oncology, namely how highly heterogeneous, drug resistant tumor cell populations develop, and how they can be targeted. Most...
Bispecific T cell engager targeting a highly specific tumor cell surface antigen
Abstract We have identified a highly tumor specific cell surface antigen, ALPPL2 or ALPG, that is not expressed in any normal tissue except for the placenta. ALPPL2 is expressed in...
ILT3 (LILRB4) in anti-tumor immunity and immunotherapy
ABSTRACT Tumor associated macrophages (TAMs) are key components of the tumor microenvironment and are associated with immunosuppression, poor prognosis and an inadequate response t...
MUC1-C is a target for advancing immunotherapy of non-small cell lung cancer
PROJECT SUMMARY Immune checkpoint inhibitors (ICIs), particularly those blocking the PD-1/PD-L1 pathway, have improved the treatment of non-small cell lung cancer (NSCLC), supporti...
Examining the Impact of Local Policies on Sociodemographic Disparities in Tobacco Use
PROJECT SUMMARY/ABSTRACT The goal of this proposed study is to examine the impact of retail policies on disparities in tobacco outcomes and allow me to establish research independe...
Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)
RFA-CA-22-025 application entitled “Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Ora...
The role, mechanism, and therapeutic potential of METTL1 in acute myeloid leukemia
PROJECT SUMMARY: Acute myeloid leukemia (AML) is a devastating hematopoietic malignancy characterized by clonal expansion of leukemia stem cells (LSCs). Despite advancements in che...